Drug Profile
Botulinum toxin vaccine - DynPort
Alternative Names: Botulism vaccine - DynPort; rBV A/B; recombinant botulinum neurotoxin vaccine; Recombinant botulinum vaccine A/BLatest Information Update: 17 Apr 2021
Price :
$50
*
At a glance
- Originator DynPort Vaccine Company LLC; United States Army Medical Research Institute of Infectious Diseases
- Developer DynPort Vaccine Company
- Class Bacterial vaccines
- Mechanism of Action Botulinum toxin inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Botulism
Most Recent Events
- 17 Apr 2021 No development reported - Phase-II for Botulism (Prevention) in USA (IM) (DynPort Vaccine Compnay pipeline, April 2021)
- 04 Dec 2018 DynPort withdraws a phase III trial in healthy volunteers in Botulism (Prevention) in USA, prior to enrolment (IM) (NCT01940315)
- 24 Oct 2018 DynPort plans to re-initiate a phase III trial in healthy volunteers in Botulism (Prevention) in USA (IM) (NCT01940315)